Additionally, there is ongoing development of target antigens like c-Met (mesenchymal-epithelial transition factor), a hepatocyte growth factor receptor, human epidermal growth factor receptor type 3 (HER3), chondroitin sulfate proteoglycan 4 (CSPG4), which plays a role in stabilizing early melanoma cells, and CD30, a tumor necrosis factor receptor and tumor marker, for various ADCS applications [125,126,127]. This evidence concerns the gene MET and melanoma.